The efficacy of low dose azathioprine/6-mercaptopurine in patients with inflammatory bowel disease

Hepato-Gastroenterology

Volumn 56, Issue 94-95, 2009, Pages 1395-1402

  Kim, Dong Uk ^a   Kim, Young Ho ^a   Kim, Beom Jin ^a   Chang, Dong Kyung ^a   Son, Hee Jung ^a   Rhee, Poong Lyul ^a   Kim, Jae J ^a   Rhee, Jong Chul ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

6 mercaptopurine; Azathioprine; Inflammatory bowel disease

Indexed keywords

AMYLASE; AZATHIOPRINE; MERCAPTOPURINE; TRIACYLGLYCEROL LIPASE;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; CROHN DISEASE; DRUG DOSE REDUCTION; DRUG EFFICACY; ENTERITIS; FEMALE; FEVER; HUMAN; LEUKOPENIA; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RECURRENCE RISK; RELAPSE; REMISSION; SIDE EFFECT; SOUTH KOREA; THROMBOCYTOPENIA; TREATMENT OUTCOME; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; ULCERATIVE COLITIS; VOMITING;

6-MERCAPTOPURINE; ADOLESCENT; ADULT; AGED; AZATHIOPRINE; FEMALE; GENOTYPE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; METHYLTRANSFERASES; MIDDLE AGED;

EID: 71949104060     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Fraser AG, Orchard TR, Jewell DP: The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002; 50:485-489.
2. Khan ZH, Mayberry JF, Spiers N, Wicks AC: Retrospective case series analysis of patients with inflammatory bowel disease on azathioprine. A district general hospital experience. Digestion 2000; 62:249-254.
3. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R: A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995; 37:674-678.
4. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C: Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2000:CD000545.
5. Pearson DC, May GR, Fick G, Sutherland LR: Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2000:CD000067.
6. Timmer A, McDonald JW, Macdonald JK: Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007:CD000478.
7. Ewe K, Press AG, Singe CC, Stufler M, Ueberschaer B, Hommel G, Meyer zum Buschenfelde KH: Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology 1993; 105:367-372.
8. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS: Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980; 302:981-987. (Pubitemid 10125406)
9. Munkholm P, Langholz E, Davidsen M, Binder V: Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994; 35:360-362. (Pubitemid 24092906)
10. Sandborn WJ: Azathioprine: state of the art in inflammatory bowel disease. Scand J Gastroenterol Suppl 1998; 225:92-99.
11. Hibi T, Naganuma M, Kitahora T, Kinjyo F, Shimoyama T: Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. J Gastroenterol 2003; 38:740-746. (Pubitemid 37161337)
12. Harvey RF, Bradshaw JM: A simple index of Crohn's-disease activity. Lancet 1980; 1:514.
13. Theodor E, Niv Y, Bat L: Imuran in the treatment of ulcerative colitis. Am J Gastroenterol 1981; 76:262-266.
14. Sandborn WJ, Tremaine WJ, Wolf DC, Targan SR, Sninsky CA, Sutherland LR, Hanauer SB, McDonald JW, Feagan BG, Fedorak RN, Isaacs KL, Pike MG, Mays DC, Lipsky JJ, Gordon S, Kleoudis CS, Murdock RH, Jr.: Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology 1999; 117:527-535.
15. Bouhnik Y, Lemann M, Mary JY, Scemama G, Tai R, Matuchansky C, Modigliani R, Rambaud JC: Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996; 347:215-219. (Pubitemid 26035245)
16. Caprilli R, Angelucci E, Cocco A, Viscido A, Annese V, Ardizzone S, Biancone L, Castiglione F, Cottone M, Meucci G, Paoluzi P, Papi C, Sturniolo GC, Vecchi M: Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement. Dig Liver Dis 2005; 37:407-417. (Pubitemid 44356045)
17. Domenech E: Inflammatory bowel disease: current therapeutic options. Digestion 2006; 73 Suppl 1:67-76. (Pubitemid 43296219)
18. Holtmann MH, Krummenauer F, Claas C, Kremeyer K, Lorenz D, Rainer O, Vogel I, Bocker U, Bohm S, Buning C, Duchmann R, Gerken G, Herfarth H, Lugering N, Kruis W, Reinshagen M, Schmidt J, Stallmach A, Stein J, Sturm A, Galle PR, Hommes DW, D'Haens G, Rutgeerts P, Neurath MF: Long-term effectiveness of azathioprine in IBD beyond 4 years: a European multicenter study in 1176 patients. Dig Dis Sci 2006; 51:1516-1524. (Pubitemid 44379292)
19. Nielsen OH, Vainer B, Rask-Madsen J: Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment Pharmacol Ther 2001; 15:1699-1708. (Pubitemid 33001133)
20. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI: 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989; 111:641-649. (Pubitemid 19259182)
21. Lennard L: TPMT in the treatment of Crohn's disease with azathioprine. Gut 2002; 51:143-146. (Pubitemid 34791433)
22. Krynetski EY, Evans WE: Genetic polymorphism of thiopurine S-methyltransferase: molecular mechanisms and clinical importance. Pharmacology 2000; 61:136-146.
23. Schaeffeler E, Lang T, Zanger UM, Eichelbaum M, Schwab M: High-throughput genotyping of thiopurine S-methyltransferase by denaturing HPLC. Clin Chem 2001; 47:548-555. (Pubitemid 32222472)
24. Weinshilboum R: Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. Drug Metab Dispos 2001; 29:601-605. (Pubitemid 32275544)
25. Reuther LO, Sonne J, Larsen N, Dahlerup JF, Thomsen OO, Schmiegelow K: Thiopurine methyltransferase genotype distribution in patients with Crohn's disease. Aliment Pharmacol Ther 2003; 17:65-68.
26. Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui CH, Relling MV, Evans WE: Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997; 126:608-614. (Pubitemid 27172187)
27. Coulthard SA, Hall AG: Recent advances in the pharmacogenomics of thiopurine methyltransferase. Pharmacogenomics J 2001; 1:254-261.
28. Ansari A, Hassan C, Duley J, Marinaki A, Shobowale-Bakre EM, Seed P, Meenan J, Yim A, Sanderson J: Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16:1743-1750.
29. Evans WE: Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Ther Drug Monit 2004; 26:186-191.
30. Kurzawski M, Gawronska-Szklarz B, Drozdzik M: Frequency distribution of thiopurine S-methyltransferase alleles in a polish population. Ther Drug Monit 2004; 26:541-545. (Pubitemid 39314323)
31. Kubota T, Chiba K: Frequencies of thiopurine S-methyltransferase mutant alleles (TPMT*2, *3A, *3B and *3C) in 151 healthy Japanese subjects and the inheritance of TPMT*3C in the family of a propositus. Br J Clin Pharmacol 2001; 51:475-477. (Pubitemid 32852986)
32. Ameyaw MM, Collie-Duguid ES, Powrie RH, Ofori-Adjei D, McLeod HL: Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum Mol Genet 1999; 8:367-370.
33. Collie-Duguid ES, Pritchard SC, Powrie RH, Sludden J, Collier DA, Li T, McLeod HL: The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 1999; 9:37-42. (Pubitemid 29176722)
34. Schaeffeler E, Fischer C, Brockmeier D, Wernet D, Moerike K, Eichelbaum M, Zanger UM, Schwab M: Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 2004; 14:407-417. (Pubitemid 38971231)
35. Sanderson J, Ansari A, Marinaki T, Duley J: Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy? Ann Clin Biochem 2004; 41:294-302.
36. Kader HA, Wenner WJ, Jr., Telega GW, Maller ES, Baldassano RN: Normal thiopurine methyltransferase levels do not eliminate 6-mercaptopurine or azathioprine toxicity in children with inflammatory bowel disease. J Clin Gastroenterol 2000; 30:409-413.
37. Gisbert JP, Nino P, Rodrigo L, Cara C, Guijarro LG: Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients. Am J Gastroenterol 2006; 101:2769-2776. (Pubitemid 44902649)
38. Gisbert JP, Luna M, Mate J, Gonzalez-Guijarro L, Cara C, Pajares JM: Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study. Hepatogastroenterology 2006; 53:399-404. (Pubitemid 43954416)
39. Corominas H, Domenech M, Gonzalez D, Diaz C, Roca M, Garcia-Gonzalez MA, Pena S, Baiget M: Allelic variants of the thiopurine S-methyltransferase deficiency in patients with ulcerative colitis and in healthy controls. Am J Gastroenterol 2000; 95:2313-2317. (Pubitemid 30707394)
40. Colombel JF, Ferrari N, Debuysere H, Marteau P, Gendre JP, Bonaz B, Soule JC, Modigliani R, Touze Y, Catala P, Libersa C, Broly F: Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118:1025-1030. (Pubitemid 30346978)
41. Szumlanski CL, Honchel R, Scott MC, Weinshilboum RM: Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics 1992; 2:148-159.
42. Jun JB, Cho DY, Kang C, Bae SC: Thiopurine S-methyltransferase polymorphisms and the relationship between the mutant alleles and the adverse effects in systemic lupus erythematosus patients taking azathioprine. Clin Exp Rheumatol 2005; 23:873-876. (Pubitemid 43040517)
43. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE: Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993; 34:1081-1085.
44. Colonna T, Korelitz BI: The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn's disease. Am J Gastroenterol 1994; 89:362-366. (Pubitemid 24074394)
45. Persley KM, Present DH: Neutropenia is not required for clinical remission during azathioprine therapy in inflammatory bowel disease. Eur J Gastroenterol Hepatol 2001; 13:1053-1055. (Pubitemid 32905197)
46. Campbell S, Ghosh S: Is neutropenia required for effective maintenance of remission during azathioprine therapy in inflammatory bowel disease? Eur J Gastroenterol Hepatol 2001; 13:1073-1076. (Pubitemid 32905201)
47. Burke DA, Dixon MF, Axon AT: Ulcerative colitis: prolonged remission following azathioprine-induced pancytopenia. J Clin Gastroenterol 1989; 11:327-330.